A 63-year-old male, who had undergone angiography using thorium dioxide (Thorotrast) at the age of 15 for investigation of a giant hemangioma on his left thigh, developed anemia in September 1986 (47 yrs after the angiography). A diagnosis of erythroleukemia was made from a bone marrowstudy which showed 56.4% megaloblastoid erythroblasts and 12.8% myeloblasts. Autopsy revealed Thorotrast deposition in the liver, spleen, bone marrow, and lymph nodes, and monotonous proliferation of myeloblasts in the bone marrow. He also had differentiated tubular adenocarcinoma of the posterior wall of the stomach.
Thorium dioxide (Thorotrast) was developed in 1930 in Germanyas a contrast mediumfor roentgenography. Thorium (232Th) is the principal ingredient of Thorotrast. Thorium is known to have a very long half-life of 1.39xl010 yrs. As
Thorotrast is insoluble in body fluids, it is readily deposited in the reticuloendothelial system where it remains for a long period. Because of these characteristics, the incidence of malignancy due to in vivo irradiation by a rays is very high following the injection of this contrast medium; in Japan, more than 10 cases of this type of leukemia have been reported. In this paper, we report a case of erythroleukemia which developed 47 yrs after intravenous Thorotrast injection for the angiographic investigation of a hemangioma of the left thigh.
CASE REPORT
A 63-year-old male had a giant hemangioma on his left thigh and left buttock which was present from birth. In 1939, at the age of 15, prior to the hemangioma surgery, he underwent angiography and Thorotrast was used as the contrast medium. He remained well until September 1986 (47 yrs after the infusion of Thorotrast), whenhe was first found to have anemia at a routine medical examination. In December 1986, he developed palpitations, fever, and cough and was admitted to Kurobe City The erythroblast in the center contains multiple nuclei, x 1250 and thigh, it was suspected that the thrombocytopenia might be a symptomof the Kasabach-Merritt syndrome. To investigate the possibility of irradiation of the giant hemangioma to improve his 2) and were PAS-positive (Fig. 3) . The myeloblasts had Auer bodies (Fig. 4) , and they were peroxidasepositive but negative for a-naphthyl butyrate esterase stain. The prothrombin time was 13.1 s, the activated partial thromboplastin time was 30.2 s, the Thrombo-test was 47.7%, and the hepaplastin test was 61.8%. His fibrinogen level was 225 mg/dl, and fibrin degradation products were less than 10^g/ml. The following clotting factor activities were noted: antithrombin III, 66%; factor II, 58%; factor V, 104%; factor VII, 30%; factor VIII, 148%; factor IX, 80%; and factor X, 48%. His total protein level was 7.8 g/dl, albumin 3.5 g/dl, SGOT 21 U/l, SGPT 48 U/l, LDH 252 U/l, and alkaline phosphatase 87 U/l. TTT was 4.9 U and ZTT was 17.1 U. A plain abdominal X-ray revealed radio-opaque material in the left hypochondrium and in the pelvic cavity (Fig. 5 ).
In the clinical course, in attempt to improve his thrombocytopenia, irradiation was used to treat the giant hemangioma(48 Gys over 29 days). However, the thrombocytopenia did not improve and epistaxis and gastrointestinal bleeding developed. He died due to gastrointestinal hemorrhageand Pseudomonas aeruginosa septicemia on April 30, 1987.
In the autopsy findings, the bone marrow showed monotonousproliferation of myeloblasts with a marked decrease in erythroblasts and megakaryocytes. Infiltrations of leukemic cells were seen in the liver, spleen, both lungs, and the kidneys. Deposition of Thorotrast was noted in the liver, spleen (Fig.  6 ), bone marrow, and lymph nodes. The Thorotrast dosimetric study of autopsy materials is presently under examination at the National Institute of Radiological Sciences. He also had a well- (Fig. 7) . But a histologically recognizable deposit of Thorotrast was not present in the stomach. Autoradiographs of the liver and stomach tissue were performed, and alpha ray tracks were detected in the liver tissue (Fig. 8) but not in the stomach tissue at 70 days exposure. following Thorotrast administration. Cases of acute myeloblastic leukemia, multiple myeloma (7), and myelodysplastic syndrome (8) have also been reported. In the Japanese cases of hematological malignancy, the latent period has ranged from 16 to 36 yrs (2). The incidence of erythroleukemia is high among the cases of acute leukemia (2, 8) , and this maybe due to damageto stem cells. The a rays from 232ThO2 aggregates trapped in the reticuloendothelial cells of the liver, spleen, bone marrow, and lymph nodes can only penetrate less than 100^m, so they only cause irradiation damage to the immediately adjacent tissue (9) .
Carcinoma of stomach is rather rare among Thorotrast-induced malignancies. Among1 03 deaths in a group of patients given Thorotrast intravascularly, 5 cases of carcinoma of the stomach were reported compared to 18 hepatic tumors (1). Six cases of gastric cancer were reported comparedto 50 cases of hepatic tumor among 151 cases of malignant Thorotrast-induced tumors in a Danish study (10) . As we could not find a histologically recognizable deposit of Thorotrast in the stomach, the direct relationship between the carcinoma of the stomach and Thorotrast in the present case is not clear.
